Search results
Results from the WOW.Com Content Network
Edgewise Therapeutics, Inc. (EWTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
For premium support please call: 800-290-4726 more ways to reach us
Novo Holdings A/S (formerly Novo A/S) [1] is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S.Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2023 was worth almost DKK 1,114 billion [2] [3] [4] Danish Kroner (approximately US$163 billion).
Semaglutide is a medication used for the treatment of type 2 diabetes and obesity.
Alvogen is a private, US-based pharmaceuticals company founded in 2009. Since 2015, it has been majority-owned by CVC Capital Partners and Temasek Holdings. [2] Alvogen focuses on so-called 'difficult-to-make' generic drugs and injectables, and both produces its own products and markets the products of brand name pharmaceutical companies.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
The company also acquired, later in the same year, Meritage Pharma for $245 million, Foresight Biotherapeutics for $300 million [24] and Dyax for $6.5 billion. [ 25 ] [ 26 ] The purchases bolstered Shires gastro-intestinal and rare disease sectors, with Phase-III-ready treatment - Budesonide - for the treatment of eosinophilic esophagitis .